Sopharma AD (BUL:SFA)

Bulgaria · Delayed Price · Currency is BGN · Price in EUR

1.930

-0.010 (-0.52%)

At close: Jun 19, 2026

72.48% (1Y)

Market Cap	1.94B +80.2%
Revenue (ttm)	2.69B +20.4%
Net Income	154.80M +81.5%
EPS	0.30 +72.0%
Shares Out	525.53M
PE Ratio	12.26
Forward PE	n/a
Dividend	0.06 (1.52%)
Ex-Dividend Date	n/a

Volume	31,630
Open	1.935
Previous Close	1.940
Day's Range	1.920 - 1.940
52-Week Range	1.105 - 2.000
Beta	0.10
Analysts	Strong Buy
Price Target	1.22 (-36.79%)
Earnings Date	Jun 1, 2026

About Sopharma AD

Sopharma AD produces, distributes, and exports pharmaceutical products in Europe, Bulgaria, and internationally. It offers Carsil to treat liver disease; Tempalgin, a painkiller; Analgin, a pain reliever; Tabex, a drug used for smoking secession; Tribestan, a drug used for stimulation of the male reproductive system; Broncholytin, which is used to suppress cough; Nivalin for use in the peripheral nervous system; Methylprednisolon for severe allergies and life-threatening conditions; Vitamin C; Valeriana, a herbal medicine to reduce the stress; ... [Read more]

Industry Pharmaceutical Preparations

Founded 1933

Employees 5,932

Stock Exchange Bulgarian Stock Exchange

Ticker Symbol SFA

Full Company Profile

Financial Performance

In 2025, Sopharma AD's revenue was 1.35 billion, an increase of 22.31% compared to the previous year's 1.10 billion. Earnings were 68.30 million, an increase of 74.61%.

Financial numbers in EUR Financial Statements